Digital From static documents to strategic capability: The case for ... Protocol documentation will become protocol ingestion – an approach that’s automated, consistent, and intelligent.
Digital Fail fast is not a cultural problem. It is a capital allocat... Even modest improvements in early predictive resolution can materially shift portfolio economics.
R&D Making AI work where it matters, with Rob DiCicco Rob DiCicco, vice president of portfolio management at Transcelerate Biopharma Inc, discusses barriers and the breakthroughs in making AI work.
R&D Agentic AI and the human element: Building trustworthy autom... The future of clinical trials isn’t about replacing people. It’s about empowering them with smarter tools.
R&D Results, reality, and recalibration: Unpacking AI hype at SC... SCOPE 2026 was dominated by one big topic: AI. You couldn’t walk five steps without hearing about something that AI was going to fix.
R&D From complexity to cohesion: AI’s growing role in building s... AI is being used from protocol design to study start-up and through clinical trial closeout, reshaping the trial lifecycle.
News New data build case for Roche's oral BTK drug for MS Roche remains confident in the prospects for its soon-to-be-filed oral BTK drug fenebrutinib for multiple sclerosis, despite safety concerns.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
